Pfizer to seek approval for RSV vaccine for people as young as 18
- Pfizer's RSV vaccine, Abrysvo, demonstrated a strong immune response in adults aged 18 to 59, protecting against RSV-associated illness.
- The vaccine trial included adults with underlying chronic conditions like asthma and diabetes, who are at higher risk of RSV.
- Hawaii Department of Health is investigating cases of pertussis, a highly contagious respiratory illness causing severe coughing fits and other complications.
Insights by Ground AI
Does this summary seem wrong?
0 Articles
0 Articles
All
Left
Center
Right
Coverage Details
Total News Sources0
Leaning Left8Leaning Right7Center33Last Updated22 days agoBias Distribution69% Center
Bias Distribution
- 69% of the sources are Center
68% Center
L 17%
C 68%
15%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage